Altered pituitary hormone secretion in patients with pseudocyesis.
Pituitary function studies were performed in two patients with pseudocyesis, one of whom was reinvestigated during a recurrent episode. There was an exaggerated prolactin response to thyrotropin-releasing hormone, an aberrant growth hormone increase, and an impaired growth hormone response to dopamine receptor agonists (apomorphine or bromocriptine). These findings point to a derangement in hypothalamic-pituitary function in pseudocyesis and may indicate an underlying impairment in dopaminergic function in this disorder.
D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage; D006133:Growth Substances / Q000097:blood; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood; D010903:Pituitary Gland, Anterior / Q000378:metabolism*; D011388:Prolactin / Q000097:blood; D011555:Pseudopregnancy / Q000209:etiology*; D012008:Recurrence; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage
D006133:Growth Substances; D007987:Gonadotropin-Releasing Hormone; D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin